Stéphane Bancel, Moderna CEO (Joel Saget/AFP via Getty Images)
January 17, 2023 04:05 PM ESTUpdated January 17, 07:18 PM
R&D

Mod­er­na jumps in­to piv­otal pack with promis­ing RSV da­ta as big ri­vals face off in megablock­buster race

John Carroll

Editor & Founder

There’s a foot race de­vel­op­ing for the lead of a multi­bil­lion-dol­lar vac­cine mar­ket. And once again, Mod­er­na $MR­NA promis­es to be right in the thick …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times